Stocks mixed into Fed meeting, new Apple MacBooks, Caterpillar and Pfizer earnings, AMD on Deck - Five Things To Know
Five things you need to know before the market opens on Tuesday October 31:1. -- Stock Market Today: Stocks mixed, Treasury yields steady ahead of Fed meeting Stocks are on pace for their worst month of the year this October, with higher Treasury yields, mounting geopolitical risks and muted big tech earnings holding down gains.2. -- Apple stocks slips following new MacBook, chip line-up ahead of Q4 earnings Investors are looking for Apple's new MacBook line-up to support a softening of sales for its iPhone 15 heading into the holiday quarter.3. -- Caterpillar shares jump as construction spending powers Q3 earnings beat Caterpillar shares will provide a solid boost for the Dow after the construction equipment giant posted much stronger-than-expected third quarter earnings.4. -- AMD earnings on deck with AI ramp, China export restrictions in focus AMD, which is looking to ramp its new generation of AI chips, will post fiscal first quarter earnings after the close of trading Tuesday.5. -- Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
Read more...
Five things you need to know before the market opens on Tuesday October 31:1. -- Stock Market Today: Stocks mixed, Treasury yields steady ahead of Fed meeting Stocks are on pace for their worst month of the year this October, with higher Treasury yields, mounting geopolitical risks and muted big tech earnings holding down gains.2. -- Apple stocks slips following new MacBook, chip line-up ahead of Q4 earnings Investors are looking for Apple's new MacBook line-up to support a softening of sales for its iPhone 15 heading into the holiday quarter.3. -- Caterpillar shares jump as construction spending powers Q3 earnings beat Caterpillar shares will provide a solid boost for the Dow after the construction equipment giant posted much stronger-than-expected third quarter earnings.4. -- AMD earnings on deck with AI ramp, China export restrictions in focus AMD, which is looking to ramp its new generation of AI chips, will post fiscal first quarter earnings after the close of trading Tuesday.5. -- Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
Read more...
TheStreet
Stocks mixed into Fed meeting, new Apple MacBooks, Caterpillar and Pfizer earnings, AMD on Deck - Five Things To Know
Stocks mixed, Apple, Caterpillar, AMD, Pfizer
*My peeled garlic suggests eating it as a snack*
submitted by /u/SwiggityStag to r/mildlyinteresting [link] [comments]
[Read more...](https://www.reddit.com/r/mildlyinteresting/comments/17k22yj/my_peeled_garlic_suggests_eating_it_as_a_snack/)
submitted by /u/SwiggityStag to r/mildlyinteresting [link] [comments]
[Read more...](https://www.reddit.com/r/mildlyinteresting/comments/17k22yj/my_peeled_garlic_suggests_eating_it_as_a_snack/)
Reddit
From the mildlyinteresting community on Reddit: My peeled garlic suggests eating it as a snack
Explore this post and more from the mildlyinteresting community
My peeled garlic suggests eating it as a snack
submitted by /u/SwiggityStag to r/mildlyinteresting link comments
Read more...
submitted by /u/SwiggityStag to r/mildlyinteresting link comments
Read more...
Reddit
From the mildlyinteresting community on Reddit: My peeled garlic suggests eating it as a snack
Explore this post and more from the mildlyinteresting community
*Leonardo DiCaprioβs new girlfriend wasn't even born when Titanic was released*
submitted by /u/BoxoutOverload to r/nottheonion [link] [comments]
[Read more...](https://www.reddit.com/r/nottheonion/comments/17kde2f/leonardo_dicaprios_new_girlfriend_wasnt_even_born/)
submitted by /u/BoxoutOverload to r/nottheonion [link] [comments]
[Read more...](https://www.reddit.com/r/nottheonion/comments/17kde2f/leonardo_dicaprios_new_girlfriend_wasnt_even_born/)
Reddit
From the nottheonion community on Reddit: Leonardo DiCaprioβs new girlfriend wasn't even born when Titanic was released
Explore this post and more from the nottheonion community
Leonardo DiCaprioβs new girlfriend wasn't even born when Titanic was released
submitted by /u/BoxoutOverload to r/nottheonion link comments
Read more...
submitted by /u/BoxoutOverload to r/nottheonion link comments
Read more...
Reddit
From the nottheonion community on Reddit: Leonardo DiCaprioβs new girlfriend wasn't even born when Titanic was released
Explore this post and more from the nottheonion community
*Evaluate*
submitted by /u/Canoodleamazed to r/memes [link] [comments]
[Read more...](https://www.reddit.com/r/memes/comments/17ke6bv/evaluate/)
submitted by /u/Canoodleamazed to r/memes [link] [comments]
[Read more...](https://www.reddit.com/r/memes/comments/17ke6bv/evaluate/)
Reddit
From the memes community on Reddit: Evaluate
Explore this post and more from the memes community
*ΠΠΎ Β«Π‘ΠΌΠ΅ΡΠ°ΡΠΈΠΊΠ°ΠΌΒ» ΡΠ½ΠΈΠΌΡΡ ΡΠΈΠ»ΡΠΌ ΡΠΎ ΡΡΠ΅Π½Π°ΡΠΈΠ΅ΠΌ Π‘Π΅ΡΠ³Π΅Ρ ΠΡΠΊΡΡΠ½Π΅Π½ΠΊΠΎ*
ΠΠ°Ρ ΠΆΠ΄ΡΡ Π½Π°ΡΡΠ½Π°Ρ ΡΠ°Π½ΡΠ°ΡΡΠΈΠΊΠ° Ρ ΠΆΠΈΠ²ΡΠΌΠΈ Π°ΠΊΡΡΡΠ°ΠΌΠΈ.
[Read more...](https://lifehacker.ru/smeshariki-film-so-scenariem-lukyanenko/)
ΠΠ°Ρ ΠΆΠ΄ΡΡ Π½Π°ΡΡΠ½Π°Ρ ΡΠ°Π½ΡΠ°ΡΡΠΈΠΊΠ° Ρ ΠΆΠΈΠ²ΡΠΌΠΈ Π°ΠΊΡΡΡΠ°ΠΌΠΈ.
[Read more...](https://lifehacker.ru/smeshariki-film-so-scenariem-lukyanenko/)
*ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π *
via forma full 5 https://ift.tt/LObds7x Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3572590.html)
via forma full 5 https://ift.tt/LObds7x Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3572590.html)
Forma-Odezhda
ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π
via forma full 5 https://ift.tt/LObds7x Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/LObds7x Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ²Π°Π½ΠΈΡ Π² Π°ΡΠΌΠΈΠΈ Π‘Π‘Π‘Π Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*ΠΠΈΠ΄Ρ ΠΈ ΡΠΎΠ΄Π° Π²ΠΎΠΉΡΠΊ ΠΠ‘*
via forma full 5 https://ift.tt/GpWvquw Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3573306.html)
via forma full 5 https://ift.tt/GpWvquw Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3573306.html)
Forma-Odezhda
ΠΠΈΠ΄Ρ ΠΈ ΡΠΎΠ΄Π° Π²ΠΎΠΉΡΠΊ ΠΠ‘ Π Π€
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΈΠ΄Ρ ΠΈ ΡΠΎΠ΄Π° Π²ΠΎΠΉΡΠΊ ΠΠ‘ Π Π€ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠΈΠ΄Ρ ΠΈ ΡΠΎΠ΄Π° Π²ΠΎΠΉΡΠΊ ΠΠ‘
via forma full 5 https://ift.tt/GpWvquw Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/GpWvquw Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠΈΠ΄Ρ ΠΈ ΡΠΎΠ΄Π° Π²ΠΎΠΉΡΠΊ ΠΠ‘ Π Π€
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΈΠ΄Ρ ΠΈ ΡΠΎΠ΄Π° Π²ΠΎΠΉΡΠΊ ΠΠ‘ Π Π€ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales*
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. βWith a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizerβs long-term growth potential,β said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/pfizer-posts-narrower-q3-loss-amid-slumping-covid-vaccine-sales)
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. βWith a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizerβs long-term growth potential,β said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/pfizer-posts-narrower-q3-loss-amid-slumping-covid-vaccine-sales)
TheStreet
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales
Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. βWith a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizerβs long-term growth potential,β said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
Updated at 7:09 am EDT Pfizer (PFE) - Get Free Report posted a narrower-than-expected third quarter loss Tuesday, while holding its recently-lowered profit forecasts in place amid the ongoing slump in Covid vaccine and treatment sales. Pfizer said its adjusted loss for the three months ended in September was pegged at 17 cents per share, down from a profit of $1.78 over the same period last year but well inside the Wall Street consensus forecast of a loss of 34 cents per share. Pfizer slashed its full-year sales and profits forecasts earlier this month amid a slump in demand for Covid treatments. The group told investors earlier this month that it would write-off around $4.6 billion in inventories of Paxlovid, its oral Covid treatment, while taking a further $5.5 billion non-cash charge against its third quarter earnings. Group revenues, Pfizer said, fell 41.5% to $13.232 billion, missing analysts' estimates of a $13.34 billion tally. Looking into the final months of the year, Pfizer said full-year group revenues would likely come in between $58 billion and $61 billion, down from its early August forecast of between $67 billion and $70 billion, amid slumping sales of its both Paxloid and its Comirnaty Covid vaccine. Pfizer also said adjusted earnings for the full-year will likely be within a range of $1.45 to $1.65 per share, well south of its August forecast of between $3.25 to $3.45 per share. βWith a significant uncertainty removed by our recently announced amended Paxlovid supply agreement with the U.S. government, our expectation of additional clarification on global vaccination and treatment rates by the end of the year, and the breakthroughs continuing to emerge from our pipeline, we look forward to concluding 2023 with positive momentum that showcases Pfizerβs long-term growth potential,β said CEO Albert Bourla Pfizer shares were marked 0.56% lower in pre-market trading immediately following the earnings release to indicate an opening bell price of $30.38 each. Investors will likely now focus on Pfizer's ability to pass on price increases for its Covid treatments, now that they've moved from government-controlled distribution. A recent trial suggesting a combination flu/Covid vaccine, which it's developing alongside its German partner BioNTech (BNTX) - Get Free Report, could also support domestic U.S. vaccine rates, currently forecast at around 17%, and the group's overall top and bottom lines. Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
TheStreet
Pfizer posts narrower Q3 loss amid slumping Covid vaccine sales
Pfizer, which warned of a $5.5 billion writedown of its Covid treatment inventories earlier this month, posted a narrower-than-expected third quarter loss Tuesday.
*RosHunter =?UTF-8?B?0JrRg9C/0LjRgtGMIC0g0KTQvtGA0LzQsCDQvtC00LXQttC00Ys=?=*
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3576492.html)
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3576492.html)
Forma-Odezhda
ΠΡΠΏΠΈΡΡ Π’ΠΎΠ²Π°ΡΡ RosHunter ΠΡΠΏΠΈΡΡ
ΠΡΠΏΠΈΡΡ Π’ΠΎΠ²Π°ΡΡ ΠΠ΄Π΅ΠΆΠ΄Π° Π΄Π»Ρ ΠΎΡ
ΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΠΎΠ΄ ΡΠΎΡΠ³ΠΎΠ²ΠΎΠΉ ΠΌΠ°ΡΠΊΠΎΠΉ Β«RosHunterΒ» ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ Π²ΡΡΠΎΠΊΠΈΠΌ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎΠΌ ΠΈΠ·Π³ΠΎΡΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΈ Π΄ΠΎΠ»Π³ΠΎΠ²Π΅ΡΠ½ΠΎΡΡΡΡ Π² ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΈ. ΠΡ Π΄Π°Π²Π½ΠΎ ΠΎΡΠ΅Π½ΠΈΠ»ΠΈ Π»ΡΠ΄ΠΈ, ΡΡΠ΅ΠΉ ΡΡΡΠ°ΡΡΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡ
ΠΎΡΠ° . ΠΠ°Ρ Π΄Π΅Π²ΠΈΠ·: Β«ΠΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΈ ΡΡΠΈΠ»ΡΒ», Ρ
ΠΎΡΠΎΡΠΎ Π·Π½Π°ΠΊΠΎΠΌ Π²ΡΠ΅ΠΌ Π½Π°ΡΠΈΠΌ ΠΏΠΎ
RosHunter =?UTF-8?B?0JrRg9C/0LjRgtGMIC0g0KTQvtGA0LzQsCDQvtC00LXQttC00Ys=?=
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/i8ysMeA Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΡΠΏΠΈΡΡ Π’ΠΎΠ²Π°ΡΡ RosHunter ΠΡΠΏΠΈΡΡ
ΠΡΠΏΠΈΡΡ Π’ΠΎΠ²Π°ΡΡ ΠΠ΄Π΅ΠΆΠ΄Π° Π΄Π»Ρ ΠΎΡ
ΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΏΠΎΠ΄ ΡΠΎΡΠ³ΠΎΠ²ΠΎΠΉ ΠΌΠ°ΡΠΊΠΎΠΉ Β«RosHunterΒ» ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ Π²ΡΡΠΎΠΊΠΈΠΌ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎΠΌ ΠΈΠ·Π³ΠΎΡΠΎΠ²Π»Π΅Π½ΠΈΡ ΠΈ Π΄ΠΎΠ»Π³ΠΎΠ²Π΅ΡΠ½ΠΎΡΡΡΡ Π² ΡΠΊΡΠΏΠ»ΡΠ°ΡΠ°ΡΠΈΠΈ. ΠΡ Π΄Π°Π²Π½ΠΎ ΠΎΡΠ΅Π½ΠΈΠ»ΠΈ Π»ΡΠ΄ΠΈ, ΡΡΠ΅ΠΉ ΡΡΡΠ°ΡΡΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡ
ΠΎΡΠ° . ΠΠ°Ρ Π΄Π΅Π²ΠΈΠ·: Β«ΠΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΈ ΡΡΠΈΠ»ΡΒ», Ρ
ΠΎΡΠΎΡΠΎ Π·Π½Π°ΠΊΠΎΠΌ Π²ΡΠ΅ΠΌ Π½Π°ΡΠΈΠΌ ΠΏΠΎ
*ΠΠΠ‘Π’ Π *
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3577485.html)
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3577485.html)
Forma-Odezhda
ΠΠΠ‘Π’ Π 12.4.189-99 Π‘ΠΠΠΠ ΠΠ°ΡΠΊΠΈ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΠ‘Π’ Π 12.4.189-99 Π‘ΠΠΠΠ ΠΠ°ΡΠΊΠΈ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠΠ‘Π’ Π
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/rixIDYF Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠΠ‘Π’ Π 12.4.189-99 Π‘ΠΠΠΠ ΠΠ°ΡΠΊΠΈ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΠ‘Π’ Π 12.4.189-99 Π‘ΠΠΠΠ ΠΠ°ΡΠΊΠΈ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ*
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3572107.html)
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3572107.html)
Forma-Odezhda
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
via forma full 5 https://ift.tt/vTJmFYy Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.